Francesco Crea

List of Publications by Year
in descending order

82 papers	3,034 citations	136740 32 h-index	168136 53 g-index
85 all docs	85 docs citations	85 times ranked	4755 citing authors

#	Article	IF	Citations
1	Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer. Oncotarget, 2014, 5, 764-774.	0.8	215
2	Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer. Molecular Cancer, 2011, 10, 40.	7.9	150
3	EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis. Cancer and Metastasis Reviews, 2012, 31, 753-761.	2.7	148
4	Plasma miRNAs as Biomarkers to Identify Patients with Castration-Resistant Metastatic Prostate Cancer. International Journal of Molecular Sciences, 2013, 14, 7757-7770.	1.8	122
5	Long non-coding RNAs in the doxorubicin resistance of cancer cells. Cancer Letters, 2021, 508, 104-114.	3.2	118
6	Epigenetics and chemoresistance in colorectal cancer: An opportunity for treatment tailoring and novel therapeutic strategies. Drug Resistance Updates, 2011, 14, 280-296.	6.5	113
7	The role of epigenetics and long noncoding RNA MIAT in neuroendocrine prostate cancer. Epigenomics, 2016, 8, 721-731.	1.0	94
8	Polycomb-mediated silencing in neuroendocrine prostate cancer. Clinical Epigenetics, 2015, 7, 40.	1.8	93
9	The non-coding transcriptome as a dynamic regulator of cancer metastasis. Cancer and Metastasis Reviews, 2014, 33, 1-16.	2.7	91
10	The long and short non-coding RNAs modulating EZH2 signaling in cancer. Journal of Hematology and Oncology, 2022, 15, 18.	6.9	89
11	Molecular Mechanisms Involved in the Synergistic Interaction of the EZH2 Inhibitor 3-Deazaneplanocin A with Gemcitabine in Pancreatic Cancer Cells. Molecular Cancer Therapeutics, 2012, 11, 1735-1746.	1.9	84
12	Polycomb genes and cancer: Time for clinical application?. Critical Reviews in Oncology/Hematology, 2012, 83, 184-193.	2.0	74
13	BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer. International Journal of Cancer, 2011, 128, 1946-1954.	2.3	73
14	Clinical significance of Polycomb gene expression in brain tumors. Molecular Cancer, 2010, 9, 265.	7.9	72
15	The emerging role of histone lysine demethylases in prostate cancer. Molecular Cancer, 2012, 11, 52.	7.9	72
16	The long non-coding RNA PCGEM1 is regulated by androgen receptor activity in vivo. Molecular Cancer, 2015, 14, 46.	7.9	71
17	Epigenetic gene regulation in stem cells and correlation to cancer. Differentiation, 2009, 78, 1-17.	1.0	70
18	Targeting autophagy in prostate cancer: preclinical and clinical evidence for therapeutic response. Journal of Experimental and Clinical Cancer Research, 2022, 41, 105.	3.5	67

#	Article	IF	Citations
19	Molecular events in neuroendocrine prostate cancer development. Nature Reviews Urology, 2021, 18, 581-596.	1.9	65
20	Cancer stem cell epigenetics and chemoresistance. Epigenomics, 2009, 1, 63-79.	1.0	64
21	Genotranscriptomic meta-analysis of the Polycomb gene CBX2 in human cancers: initial evidence of an oncogenic role. British Journal of Cancer, 2014, 111, 1663-1672.	2.9	64
22	The epigenetic/noncoding origin of tumor dormancy. Trends in Molecular Medicine, 2015, 21, 206-211.	3.5	59
23	Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancer. Clinical Epigenetics, 2016, 8, 16.	1.8	55
24	Histone lysine demethylases in breast cancer. Critical Reviews in Oncology/Hematology, 2013, 86, 97-103.	2.0	53
25	Integrated analysis of the prostate cancer smallâ€nucleolar transcriptome reveals SNORA55 as a driver of prostate cancer progression. Molecular Oncology, 2016, 10, 693-703.	2.1	48
26	Heterochromatin Protein 1Î± Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer. Cancer Research, 2018, 78, 2691-2704.	0.4	48
27	Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients. BMC Cancer, 2010, 10, 511.	1.1	47
28	An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients. Annals of Oncology, 2012, 23, 1207-1213.	0.6	40
29	Identification of DEK as a potential therapeutic target for neuroendocrine prostate cancer. Oncotarget, 2015, 6, 1806-1820.	0.8	40
30	Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines. Molecular Cancer Therapeutics, 2009, 8, 1964-1973.	1.9	39
31	miR-100-5p inhibition induces apoptosis in dormant prostate cancer cells and prevents the emergence of castration-resistant prostate cancer. Scientific Reports, 2017, 7, 4079.	1.6	37
32	EZH2 inhibition: aÂpromisingÂstrategy to prevent cancer immune editing. Epigenomics, 2020, 12, 1457-1476.	1.0	37
33	Optical biosensors to analyze novel biomarkers in oncology. Journal of Biophotonics, 2011, 4, 442-452.	1.1	31
34	Pharmacogenomics in non-small-cell lung cancer chemotherapy. Advanced Drug Delivery Reviews, 2009, 61, 408-417.	6.6	30
35	An aromatase polymorphism (g.132810C>T) predicts risk of bisphosphonate-related osteonecrosis of the jaw. Biomarkers in Medicine, 2012, 6, 201-209.	0.6	30
36	The long noncoding <scp>RNA </scp><scp>HORAS</scp>5 mediates castrationâ€resistant prostate cancer survival by activating the androgen receptor transcriptional program. Molecular Oncology, 2019, 13, 1121-1136.	2.1	28

#	Article	IF	Citations
37	Pharmacologic rationale for early G-CSF prophylaxis in cancer patients and role of pharmacogenetics in treatment optimization. Critical Reviews in Oncology/Hematology, 2009, 72, 21-44.	2.0	24
38	Pharmacogenomics and cancer stem cells: a changing landscape?. Trends in Pharmacological Sciences, 2011, 32, 487-494.	4.0	23
39	Hypoxia and Noncoding RNAs in Taxane Resistance. Trends in Pharmacological Sciences, 2018, 39, 695-709.	4.0	23
40	Polycomb genes are associated with response to imatinib in chronic myeloid leukemia. Epigenomics, 2015, 7, 757-765.	1.0	22
41	The evolutionarily conserved long nonâ€coding RNA LINC00261 drives neuroendocrine prostate cancer proliferation and metastasis via distinct nuclear and cytoplasmic mechanisms. Molecular Oncology, 2021, 15, 1921-1941.	2.1	22
42	Targeting Prostate Cancer Stem Cells. Anti-Cancer Agents in Medicinal Chemistry, 2009, 9, 1105-1113.	0.9	21
43	Synergistic Cytotoxicity and Molecular Interaction on Drug Targets of Sorafenib and Gemcitabine in Human Pancreas Cancer Cells. Chemotherapy, 2010, 56, 303-312.	0.8	21
44	A single nucleotide polymorphism in EZH2 predicts overall survival rate in patients with cholangiocarcinoma. Oncology Letters, 2013, 6, 1487-1491.	0.8	21
45	LncRNA HORAS5 promotes taxane resistance in castration-resistant prostate cancer via a BCL2A1-dependent mechanism. Epigenomics, 2020, 12, 1123-1138.	1.0	17
46	Prognostic relevance of a T-type calcium channels gene signature in solid tumours: A correlation ready for clinical validation. PLoS ONE, 2017, 12, e0182818.	1.1	17
47	Faithful Markers of Circulating Cancer Stem Cells: Is CD133 Sufficient for Validation in Clinics?. Journal of Clinical Oncology, 2011, 29, 3487-3488.	0.8	14
48	Tâ€type calcium channels drive the proliferation of androgenâ€receptor negative prostate cancer cells. Prostate, 2019, 79, 1580-1586.	1.2	14
49	Mutational analysis of Polycomb genes in solid tumours identifies PHC3 amplification as a possible cancer-driving genetic alteration. British Journal of Cancer, 2013, 109, 1699-1702.	2.9	13
50	Treatment-emergent neuroendocrine prostate cancer: molecularly driven clinical guidelines. International Journal of Endocrine Oncology, 2019, 6, IJE20.	0.4	12
51	Histone code, human growth and cancer. Oncotarget, 2012, 3, 1-2.	0.8	12
52	HAR1: an insight into lncRNA genetic evolution. Epigenomics, 2021, 13, 1831-1843.	1.0	12
53	Age-related ultrastructural neurovascular changes in the female mouse cortex and hippocampus. Neurobiology of Aging, 2021, 101, 273-284.	1.5	11
54	Histone Modifications, Stem Cells and Prostate Cancer. Current Pharmaceutical Design, 2014, 20, 1687-1697.	0.9	11

#	Article	IF	Citations
55	Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer. BMC Cancer, 2015, 15, 874.	1.1	10
56	EZH2and cancer stem cells: fact or fiction?. Epigenomics, 2011, 3, 127-128.	1.0	9
57	The potential role of PHF6 as an oncogene: a genotranscriptomic/proteomic meta-analysis. Tumor Biology, 2016, 37, 5317-5325.	0.8	9
58	Targeting SARS-CoV-2 using polycomb inhibitors as antiviral agents. Epigenomics, 2020, 12, 811-812.	1.0	9
59	A non-canonical role for pyruvate kinase M2 as a functional modulator of Ca2+ signalling through IP3 receptors. Biochimica Et Biophysica Acta - Molecular Cell Research, 2022, 1869, 119206.	1.9	9
60	EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle. Annals of Oncology, 2012, 23, 1370-1371.	0.6	7
61	Is HOTAIR really involved in neuroendocrine prostate cancer differentiation?. Epigenomics, 2018, 10, 1259-1261.	1.0	7
62	Topoisomerase 1 Promoter Variants and Benefit from Irinotecan in Metastatic Colorectal Cancer Patients. Oncology, 2016, 91, 283-288.	0.9	5
63	Elevated expression of a pharmacologic Polycomb signature predicts poor prognosis in gastric and breast cancer. Epigenomics, 2017, 9, 1329-1335.	1.0	5
64	The Long Non-Coding RNA H19 Drives the Proliferation of Diffuse Intrinsic Pontine Glioma with H3K27 Mutation. International Journal of Molecular Sciences, 2021, 22, 9165.	1.8	4
65	Predictive significance of circulating histones in hepatocellular carcinoma patients treated with sorafenib. Epigenomics, 2022, 14, 507-517.	1.0	4
66	The role of histone lysine demethylases in cancer cellsâ€™ resistance to tyrosine kinase inhibitors. Cancer Drug Resistance (Alhambra, Calif), 2019, 2, 326-334.	0.9	2
67	Pharmacogenetics in oncology. European Journal of Cancer, Supplement, 2008, 6, 74-78.	2.2	1
68	EZH2 Single Nucleotide Variants (SNVs): Diagnostic and Prognostic Role in 10 Solid Tumor Types. Epigenomes, 2017, 1, 18.	0.8	1
69	Biological and Clinical Evidence for Metabolic Dormancy in Solid Tumors Post Therapy. Cancer Drug Discovery and Development, 2017, , 17-29.	0.2	1
70	Immuno-oncology of Dormant Tumours. Cancer Drug Discovery and Development, 2017, , 51-60.	0.2	1
71	Long Non-coding RNAs and Cancer Cellsâ€™ Drug Resistance: An Unexpected Connection. RNA Technologies, 2020, , 167-198.	0.2	1
72	Biological significance of DNA methylation patterns in human progenitor cells. Epigenomics, 2011, 3, 12-3.	1.0	1

#	Article	IF	Citations
73	Research Highlights. Epigenomics, 2011, 3, 11-13.	1.0	0
74	Prognostic Value of CD133 Caused by Mutant K-Ras and B-Rafâ€"Letter. Clinical Cancer Research, 2012, 18, 4473-4473.	3.2	0
75	Trithorax Genes in Prostate Cancer. , 0, , .		0
76	Genomeâ€"epigenome interactions: the Polycomb paradox. Epigenomics, 2014, 6, 5-7.	1.0	0
77	Are there any HOTTIPs for defining coding potential of lncRNAs, or just a lot of HOTAIR?. Epigenomics, 2017, 9, 1045-1047.	1.0	0
78	Pharmacogenetics of Angiogenesis. , 2010, , 233-242.		0
79	Evaluation of EZH2 SNPs in cholangiocarcinoma patients.. Journal of Clinical Oncology, 2012, 30, 10611-10611.	0.8	0
80	Targeting Cancer Stem Cell Efficient DNA Repair Pathways: Screening for New Therapeutics. , 2013, , 157-172.		0
81	The Nonâ€Coding Transcriptome as a Dynamic Regulator of Prostate Cancer Metastasis. FASEB Journal, 2015, 29, 221.3.	0.2	0
82	Induced pluripotent stem cells derived from liver disease patients can differentiate into functional hepatocytes. Epigenomics, 2011, 3, 13.	1.0	0